Penta Vaccine: Diseases Covered, Schedule & Side Effects

The pentavalent vaccine, widely known as the “penta vaccine,” protects against five infectious diseases in a single shot: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and Haemophilus influenzae type b (Hib).¹ It has become one of the most important vaccines in childhood immunization programs worldwide, particularly in low- and middle-income countries where these five diseases still cause serious illness and death. The combination format means fewer injections for infants and simpler logistics for health systems, which matters more than it might sound.

The Five Diseases and Why They Were Combined

Each of the five diseases targeted by the penta vaccine poses a distinct threat, especially to young children. Diphtheria produces a thick coating in the throat that can block the airway and damage the heart. Tetanus, caused by bacteria found in soil and dust, triggers severe muscle spasms that can be fatal in newborns and infants. Pertussis causes violent coughing fits that can last weeks, and in very young babies it can lead to pneumonia, brain damage, or death. Hepatitis B attacks the liver and, when acquired in infancy, frequently becomes a chronic lifelong infection that raises the risk of liver cancer decades later. Hib disease causes bacterial meningitis, pneumonia, and other invasive infections in children under five.

Before combination vaccines existed, protecting a child against all five diseases required separate injections at multiple visits. The pentavalent vaccine bundles these antigens into one vial. By 2011, it had been introduced in nearly all countries eligible for support from Gavi, the global vaccine alliance.¹ That rollout was a turning point for global childhood immunization, because it made it practical for health systems with limited cold-chain capacity and staffing to reach children with protection against diseases that had previously required a more complicated schedule.

The Standard Schedule

Most national immunization programs follow the WHO-recommended schedule of three primary doses given at 6, 10, and 14 weeks of age. In Laos, for example, the national program schedules the pentavalent vaccine at those same intervals, with the goal of completing the primary course by 14 weeks and no later than 6 months of age.² Some countries use a 2, 4, and 6 month schedule instead, depending on their overall immunization calendar and local disease epidemiology. Either way, the first dose typically arrives within the first two months of life, when maternal antibodies start to wane and the child becomes vulnerable.

Timeliness matters. Delays between doses reduce the window of early protection and can leave infants exposed during the months when diseases like pertussis and Hib meningitis are most dangerous. In many countries, getting infants to all three appointments on time remains a significant challenge, particularly in rural areas or where health facilities are far apart.

Whole-Cell Versus Acellular Pertussis

Not all penta vaccines are identical, and the biggest difference between formulations comes down to the pertussis component. Vaccines containing whole-cell pertussis (wP) use killed but intact pertussis bacteria, while acellular pertussis (aP) vaccines use only a few purified proteins from the bacterium. This distinction matters for both side effects and long-term protection.

Whole-cell formulations are more reactogenic. A randomized trial comparing a pentavalent acellular vaccine (DTaP-IPV-Hib) to a whole-cell combination (DTwP-Hib) in UK infants found that local reactions, fever above 37.5°C, reduced feeding, decreased activity, and irritability were all less common with the acellular version after each dose.³ The trade-off, though, is that population-level evidence suggests whole-cell vaccines provide longer-lasting immunity against pertussis and better overall disease protection than acellular versions.⁴ Switching entirely from whole-cell to acellular pertussis trades better tolerability for weaker long-term protection.⁵

This is why most low- and middle-income countries continue to use whole-cell pentavalent vaccines. The higher rate of mild side effects is considered acceptable given the superior and more durable protection, especially in settings where booster doses later in childhood are harder to deliver reliably. Wealthier countries with robust booster programs tend to use acellular formulations, accepting the need for more frequent boosters to maintain pertussis immunity.

Common Side Effects

The penta vaccine, like most childhood vaccines, causes local and mild systemic reactions in a sizable proportion of infants. A large surveillance study in Iran tracked side effects in the 48 hours following pentavalent vaccination and found the following rates:⁶

Pain at the injection site: about 44% of infants
Irritability: about 33%
Drowsiness: about 20%
Swelling: about 16%
Loss of appetite: about 15%
Mild fever: about 13%
Redness: about 11%
Persistent crying: about 6%
Vomiting: about 5%
High fever: about 0.1%

No cases of convulsion or encephalopathy were recorded in that surveillance.⁶ In another trial comparing two formulations of a pentavalent vaccine delivered via different injection systems, tenderness at the injection site was common in both groups (around 76–86%) but no serious adverse events related to the vaccine occurred.⁷

Most of these reactions are self-limiting, meaning they resolve within a day or two without treatment. Parents are typically advised to watch for fever, keep the child comfortable, and contact a healthcare provider if symptoms are unusually severe or persist beyond 48 hours. The reactions tend to be more noticeable after the first dose and may occur with somewhat different intensity after subsequent doses.

Rare but Serious Adverse Events

Febrile seizures are the rare adverse event that generates the most concern. These are brief convulsions triggered by a rapid rise in body temperature, and they can occur after any vaccine that causes fever. A safety signal analysis from El Salvador found that the rate of febrile seizures following pentavalent vaccination exceeded the WHO’s expected background rate of six cases per 100,000 doses from April 2019 onward, peaking at about 9 per 100,000 in September. The first booster dose had the highest rate, roughly 15 per 100,000 doses, more than double the expected rate.⁸

To put those numbers in context, even at the elevated rate, this means roughly 1 in 7,000 booster doses resulted in a reported febrile seizure. Febrile seizures in young children, while frightening for parents, are generally benign and do not cause lasting neurological damage. Still, the El Salvador finding was flagged as a safety signal warranting investigation, because it showed a pattern specific to that vaccine in that time period. Such signals do not necessarily mean the vaccine itself is unsafe; they can also reflect a change in the vaccine product, manufacturing lot, or reporting behavior.

How Well the Vaccine Works

The pentavalent vaccine produces strong immune responses against all five target diseases. In a US randomized trial, an acellular pentavalent vaccine (DTaP5-IPV-Hib) generated seroprotection and seroresponse rates that were non-inferior to the same antigens given as separate licensed vaccines, both after the infant series and after a fourth dose.⁹ In plain terms, combining the antigens into one shot does not weaken the immune response compared to giving each vaccine separately.

For hepatitis B specifically, one trial found that over 99% of infants achieved seroprotection after three doses of a whole-cell pentavalent vaccine.¹⁰ A separate study tracked hepatitis B antibody levels over time in children who received pentavalent versus hexavalent vaccines and found that while antibody levels declined in both groups over the years, most children retained protective levels through age seven, though a significantly higher proportion in the hexavalent group maintained protective antibody concentrations at each annual time point.¹¹

Duration of Immunity and the Need for Boosters

The primary three-dose series builds a strong initial immune response, but protection does not last forever for every component. A study tracking children who received pentavalent vaccines through their second year of life found that primary immunization induced excellent immunity lasting into the second year, and a booster dose with a quadrivalent (DTwP-Hib) vaccine produced a strong anamnestic (memory) response to all components.¹²

By age five or six, the picture is more mixed. A study of children who had received a whole-cell pentavalent primary series and an acellular pentavalent booster found that more than 90% still had protective antibody levels for Hib, tetanus, diphtheria, and polio before a second booster. Pertussis antibody levels, however, had dropped to very low levels. After a second booster at that age, all children achieved protective levels for tetanus, diphtheria, and polio, and over 90% showed a strong rise in pertussis antibodies.¹³

The takeaway is that pertussis immunity wanes the fastest. This is consistent with the broader pattern seen worldwide: whooping cough is the component most likely to need repeated boosting throughout childhood and even into adolescence. The other four components tend to hold up better after the initial series and one or two boosters.

Giving It Alongside Other Vaccines

Infants receive multiple vaccines during the same period of life, so pediatricians and immunization programs need to know whether the penta vaccine plays well with others. The evidence is reassuring. A review of studies examining co-administration of a meningococcal B vaccine (4CMenB) with pentavalent or hexavalent vaccines, pneumococcal conjugate vaccine, and rotavirus vaccine found no significant safety signals when these vaccines were given at the same visit.¹⁴

When researchers in Thailand compared immune responses to rotavirus and pneumococcal conjugate vaccines given alongside either a hexavalent or a pentavalent combination, responses were comparable in both groups.¹⁵ Similarly, a European trial using a mixed hexavalent-pentavalent primary series found high seroprotection rates across all antigens (generally over 99% after the primary series and over 95% after a booster), with co-administered pneumococcal, rotavirus, and meningococcal C vaccines not interfering with any component’s immune response.¹⁵ In short, the penta vaccine does not blunt the effectiveness of other vaccines given on the same day, and vice versa.

Cold Chain Challenges and Supply Logistics

The penta vaccine is a liquid vaccine that must be stored between 2°C and 8°C and must never be frozen, because freezing destroys the hepatitis B and Hib components. This cold-chain requirement is one of the biggest practical constraints in delivering the vaccine to remote areas in tropical countries, where refrigeration is unreliable and transport distances are long.

A modeling study of Niger’s vaccine supply chain found that making the pentavalent vaccine thermostable (able to tolerate heat without losing potency) would have the single largest impact on the entire immunization program. It could increase the pentavalent vaccine’s own availability from 87% to 97%, and improve availability of all other non-thermostable vaccines in the supply chain to over 93%, because the pentavalent vaccine is the most space-consuming product in the cold chain.¹⁶ Innovations like microneedle patch delivery systems, which might reduce cold-chain needs, have also been modeled and shown modest improvements in vaccine availability.¹⁷

Cost is another logistic consideration. The pentavalent vaccine itself is more expensive per dose than the older DTP vaccine it replaced, but combining five antigens into one injection saves money on syringes, storage, health worker time, and clinic visits. An analysis in The Gambia found that switching to the pentavalent vaccine saved about $0.45 per fully immunized child when all delivery costs were factored in.¹⁸

Impact on Child Survival

The pentavalent vaccine did not roll out in isolation. It arrived alongside broader immunization support from Gavi, which bundled financial assistance, supply guarantees, and health system strengthening. Disentangling the penta vaccine’s specific contribution from these broader efforts is difficult, but the aggregate picture is striking. One analysis estimated that Gavi eligibility led to an average reduction of about 6 infant deaths and 12 under-five deaths per 1,000 live births over the study period, corresponding to roughly a 9% drop in the infant mortality rate and a 12% drop in under-five mortality. The authors noted these reductions were not from any single vaccine but from the combined effect of new vaccine introductions and health system improvements.¹⁹ A separate economic analysis estimated that Gavi’s vaccine programs saved around 1.5 million lives at a cost of roughly $9,000 per life saved.²⁰

The pentavalent vaccine was the centerpiece of Gavi’s early strategy, so it contributed substantially to these numbers. Before its introduction, many countries had no routine Hib or hepatitis B vaccination for infants. Adding those protections through the combination vaccine prevented cases of bacterial meningitis and chronic liver disease that would otherwise have accumulated silently for decades.

The Shift Toward Hexavalent Vaccines

As countries transition away from oral polio vaccine toward injectable inactivated polio vaccine (IPV), a natural next step is combining IPV with the pentavalent vaccine to create a hexavalent (six-in-one) vaccine. Several countries have already adopted hexavalent vaccines, and others are evaluating the switch. India, for instance, has assessed the economic implications of replacing its pentavalent plus separate IPV doses with a single hexavalent vaccine, finding potential for both logistic simplification and further injection reduction.²¹

Webinar-based training programs have been developed to help national immunization advisory groups evaluate the evidence for transitioning from pentavalent-plus-IPV to hexavalent vaccines, reflecting how seriously this shift is being taken at a policy level.²² One practical concern with hexavalent vaccines is maintaining comparable hepatitis B antibody persistence. As noted earlier, hexavalent-vaccinated children tend to maintain higher hepatitis B antibody levels over time than pentavalent-vaccinated children, which is an argument in favor of the switch where it is affordable.¹¹

The pentavalent vaccine is unlikely to disappear overnight. For many countries, particularly those still using oral polio vaccine or those where hexavalent supply and pricing are not yet favorable, the five-in-one shot will remain the backbone of infant immunization for years to come. The evolution from three-in-one DTP to five-in-one pentavalent to six-in-one hexavalent follows a consistent logic: protect against more diseases with fewer injections, reduce the burden on parents and clinics, and close gaps in immunization coverage that individual shots leave open.